Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Inui

Showing results (101-110 of 106) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 106 results.
The Journal of Clinical Investigation|September 7, 2001
Vascular endothelial dysfunction resulting from L-arginine deficiency in a patient with lysinuric protein intoleranceY Kamada, H Nagaretani, S Tamura, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|March 31, 2000
An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular wallsY Okamoto, Y Arita, M Nishida, et al.
Journal of Viral Hepatitis|August 2, 2014
The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1T Oze, N Hiramatsu, T Yakushijin, et al.
Journal of Viral Hepatitis|April 11, 2014
Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirinN Harada, N Hiramatsu, T Oze, et al.
Journal of Viral Hepatitis|June 26, 2009
Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirinT Oze, N Hiramatsu, T Yakushijin, et al.
Journal of Viral Hepatitis|June 26, 2009
Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirinN Hiramatsu, T Oze, T Yakushijin, et al.
Pageof 11

Showing results (101-110 of 106) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 106 results.
The Journal of Clinical Investigation|September 7, 2001
Vascular endothelial dysfunction resulting from L-arginine deficiency in a patient with lysinuric protein intoleranceY Kamada, H Nagaretani, S Tamura, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|March 31, 2000
An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular wallsY Okamoto, Y Arita, M Nishida, et al.
Journal of Viral Hepatitis|August 2, 2014
The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1T Oze, N Hiramatsu, T Yakushijin, et al.
Journal of Viral Hepatitis|April 11, 2014
Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirinN Harada, N Hiramatsu, T Oze, et al.
Journal of Viral Hepatitis|June 26, 2009
Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirinT Oze, N Hiramatsu, T Yakushijin, et al.
Journal of Viral Hepatitis|June 26, 2009
Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirinN Hiramatsu, T Oze, T Yakushijin, et al.
Pageof 11